The signal pathways and treatment of cytokine storm in COVID-19

L Yang, X **e, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

G Li, E De Clercq - Nature reviews Drug discovery, 2020 - nature.com
Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)

W Alhazzani, MH Møller, YM Arabi, M Loeb… - Intensive care …, 2020 - Springer
Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …

A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19

B Cao, Y Wang, D Wen, W Liu, J Wang… - New England journal …, 2020 - Mass Medical Soc
Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open …

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort …

KKW To, OTY Tsang, WS Leung, AR Tam… - The Lancet infectious …, 2020 - thelancet.com
Summary Background Coronavirus disease 2019 (COVID-19) causes severe community
and nosocomial outbreaks. Comprehensive data for serial respiratory viral load and serum …

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

BE Young, SWX Ong, S Kalimuddin, JG Low, SY Tan… - Jama, 2020 - jamanetwork.com
Importance Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in
Wuhan, China, in December 2019 and has spread globally with sustained human-to-human …

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

TP Sheahan, AC Sims, SR Leist, A Schäfer… - Nature …, 2020 - nature.com
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a
severe respiratory disease associated with more than 2468 human infections and over 851 …

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised …

IFN Hung, KC Lung, EYK Tso, R Liu, TWH Chung… - The Lancet, 2020 - thelancet.com
Background Effective antiviral therapy is important for tackling the coronavirus disease 2019
(COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b …

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

PW Horby, M Mafham, JL Bell, L Linsell, N Staplin… - The Lancet, 2020 - thelancet.com
Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the
basis of in vitro activity, preclinical studies, and observational studies. Here, we report the …

Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children

P Zimmermann, N Curtis - The Pediatric infectious disease journal, 2020 - journals.lww.com
Coronaviruses (CoVs) are a large family of enveloped, single-stranded, zoonotic RNA
viruses. Four CoVs commonly circulate among humans: HCoV2-229E,-HKU1,-NL63 and …